Cory demonstrates the potential to activate the Nrf2 signaling pathway, effectively countering oxidative stress, and simultaneously inhibit the calcineurin-Nfatc1 signaling pathway to regulate the terminals of calcium signaling. These dual effects collectively reduce osteoclast activity, ultimately contributing to a therapeutic role in RA osteolysis. Therefore, our study presents Cory as a novel pharmaceutical candidate for the prevention and treatment of RA.
Keyphrases
- signaling pathway
- rheumatoid arthritis
- oxidative stress
- disease activity
- reactive oxygen species
- induced apoptosis
- pi k akt
- epithelial mesenchymal transition
- ankylosing spondylitis
- interstitial lung disease
- dna damage
- systemic lupus erythematosus
- bone loss
- endoplasmic reticulum stress
- idiopathic pulmonary fibrosis
- human health
- heat shock protein